首页> 美国卫生研究院文献>Mediterranean Journal of Hematology and Infectious Diseases >Life-Threatening Autoimmune Hemolytic Anemia and Idhiopatic Thrombocytopenic Purpura. Successful Selective Splenic Artery Embolization
【2h】

Life-Threatening Autoimmune Hemolytic Anemia and Idhiopatic Thrombocytopenic Purpura. Successful Selective Splenic Artery Embolization

机译:危及生命的自身免疫性溶血性贫血和特发性血小板减少性紫癜。成功的选择性脾动脉栓塞术

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Selective splenic artery embolization (SSAE) is a nonsurgical intervention characterized by the transcatheter occlusion of the splenic artery and/or its branch vessels using metallic coils or other embolic devices. It has been applied for the management of splenic trauma, hypersplenism with portal hypertension, hereditary spherocytosis, thalassemia and splenic hemangioma. We hereby describe a case of a patient affected by idiopathic thrombocytopenic purpura (ITP) and warm auto-immune hemolytic anemia (AIHA) both resistant to immunosuppressive and biological therapies, not eligible for a surgical intervention because of her critical conditions. She underwent SSAE and achieved a hematologic complete response within a few days without complications. SSAE is a minimally invasive procedure to date not considered a standard option in the management of AIHA and ITP. However, following the progressive improvement of the techniques, its indications have been extended, with a reduction in morbidity and mortality compared to splenectomy in patients with critical clinical conditions. SSAE was a lifesaving therapeutic approach for our patient and it may represent a real alternative for the treatment of resistant AIHA and ITP patients not eligible for splenectomy.
机译:选择性脾动脉栓塞术(SSAE)是一种非手术干预,其特征在于使用金属线圈或其他栓塞装置经导管阻塞脾动脉和/或其分支血管。它已被用于治疗脾外伤,脾功能亢进合并门脉高压症,遗传性球囊病,地中海贫血和脾血管瘤。我们在此描述一例患者,患有特发性血小板减少性紫癜(ITP)和温暖的自身免疫溶血性贫血(AIHA),它们均对免疫抑制和生物疗法有抵抗力,由于她的病情危急,因此不适合进行外科手术。她接受了SSAE,并在几天内达到了血液学完全缓解而无并发症。迄今为止,SSAE是微创手术,在AIHA和ITP的管理中尚未被视为标准选项。但是,随着技术的逐步改进,与具有严重临床疾病的患者的脾切除术相比,其适应症得到了扩展,发病率和死亡率均降低。 SSAE对我们的患者是一种挽救生命的治疗方法,它可能是治疗不适合进行脾切除术的耐药AIHA和ITP患者的真正替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号